Vecoy Nanomedicines

Company Overview

Snapshot

Founded in October 2010 by Erez Livneh, Vecoy Nanomedicines operates with 1–10 employees. The company has raised $2M across one funding round. In December 2013, Vecoy Nanomedicines received an outer-space research prize for its virus-killing technology.

Business overview

Vecoy Nanomedicines develops novel nano-scale virus traps designed to capture and destroy viruses. Its patent-pending technology mimics human host cells, acting as virus decoys to target viruses before cellular infection. This approach aims to overcome challenges associated with existing antiviral treatments, such as virus resistance and toxicity effects, serving the Health Tech & Life Sciences sector, particularly in pharmaceuticals and drug delivery.

Strategic signal

In June 2016, Vecoy Nanomedicines secured a patent for its pathogen and substance traps. This patent validates the company's innovative approach to antiviral therapy, reinforcing its intellectual property in the nanotechnology and drug delivery space, and signaling a commitment to protecting its core technology.

Company Intelligence Q&A

When was Vecoy Nanomedicines founded?

Vecoy Nanomedicines was founded in October 2010.

Who founded Vecoy Nanomedicines?

Vecoy Nanomedicines was founded by Erez Livneh, M.Sc.

What significant recognition did Vecoy Nanomedicines receive in 2013?

In December 2013, Vecoy Nanomedicines received an outer-space research prize for its virus-killing technology.

What was a key intellectual property milestone for Vecoy Nanomedicines?

In June 2016, Vecoy Nanomedicines secured a patent for its pathogen and substance traps, highlighting its innovative approach to antiviral therapy.